PURPOSE: To review the published clinical data on @entity1149 treated with radical radiotherapy to confirm a dose-response relationship as a basis for further dose-escalation trials. METHODS: Twenty-four published clinical trials were identified, 16 of which - with 29 different standard, hyper- and hypofractionated treatment schedules - were analysed. Prescription doses were converted to biologically-equivalent dose (BED), with a correction for repopulation. Disease-free survival data were corrected for the stage profile of each cohort to allow better comparison of results. We also analysed moderate (grade II and III) lung and oesophageal acute @entity137 related to the corrected BED delivered to the @entity5 . RESULTS: The clinical data analysed showed good agreement between the observed and modelled disease-free survival at 2 years when compared to the published models of Fenwick (correlation coefficient 0.525, p=0.003) and Martel (correlation coefficient 0.492, p=0.007), indicating a clear @entity5 dose-response. In the normally fractionated treatments (    2 Gy per fraction), improved disease-free survival was generally observed in the shorter schedules (maximum around 6 weeks). However, the best outcomes were obtained for the hypofractionated schedules. No systematic relationship was seen between prescribed dose and lung or oesophageal acute @entity137 , possibly due to dose selection depending on V(20) or @entity8431 in some studies and the diversity of the @entity1 analysed. CONCLUSIONS: We have demonstrated a dose-response relationship for NSCLC based on clinical data. The clinical data provide a rational basis for selection of dose escalation schedules to be tested in future randomised trials.

Dose escalation for XXXX : analysis and modelling of published literature.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['non-small cell lung cancer'] @entity8431 :: ('MESH:D007966', 'Disease') :: ['MLD']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']
